TGA extends the use of Bayer contraceptive to eight years

This is a preview of subscriber content

Subscribe now to continue reading.

Manoj Saxena, CEO of Bayer Australia and New Zealand and country division head for the Pharmaceutical Division, said, “As a leading company in women’s healthcare, Bayer is committed to offering modern innovations as well as advances in the use of trusted products like Mirena, which has been used in Australia for more than 20 years." …

Subscribe now to continue reading.

TGA extends the use of Bayer contraceptive to eight years

This is a preview of subscriber content

Latest Video

Most Read

Given the official use of AI, a cease and desist would not be unreasonable

Telix announces takeover of ITM to create a global radiopharmaceutical powerhouse

Officials are using AI to create efficiencies in the HTA evaluation process

New AI contribution tool delivers 150 patient voices to the PBAC

Treasury has moved on from the PBS, but the policies built on its error have not

New Stories

Medicines Australia seeks answers on AI in HTA process

The prevention gap and inside Sally Panton's bet on cellular health

Pfizer 'deeply disappointed' in response to PBAC refusing to move on price

Lilly goes direct with a patient platform for its non-PBS medicines

A 'multistakeholder' reference group to shadow agreement negotiations

If there is a productivity gain in the process, then it should be passed on

Given the official use of AI, a cease and desist would not be unreasonable

Sign In

TGA extends the use of Bayer contraceptive to eight years

This is a preview of subscriber content

Latest Video

Most Read

Given the official use of AI, a cease and desist would not be unreasonable

Telix announces takeover of ITM to create a global radiopharmaceutical powerhouse

Officials are using AI to create efficiencies in the HTA evaluation process

New AI contribution tool delivers 150 patient voices to the PBAC

Treasury has moved on from the PBS, but the policies built on its error have not

Follow Us

New Stories

Medicines Australia seeks answers on AI in HTA process

The prevention gap and inside Sally Panton's bet on cellular health

Pfizer 'deeply disappointed' in response to PBAC refusing to move on price

Lilly goes direct with a patient platform for its non-PBS medicines

A 'multistakeholder' reference group to shadow agreement negotiations

If there is a productivity gain in the process, then it should be passed on

Given the official use of AI, a cease and desist would not be unreasonable